Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448887 | 0.72 | HTR6 (0.41) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL7960264 | 0.72 | HTR6 (0.41) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL17073935 | 0.70 | HTR6 (0.40) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL21694409 | 0.70 | HTR6 (0.40) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL30057710 | 0.70 | HTR6 (0.40) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL12743937 | 0.70 | HTR6 (0.44) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL308272 | 0.70 | HTR6 (0.40) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL30041622 | 0.70 | HTR6 (0.48) | HTR6MAOACES1MAOBLMNA | |
| SCHEMBL6925588 | 0.70 | HTR6 (0.48) | HTR6MAOACES1MAOBLMNA | |
| SCHEMBL308273 | 0.70 | HTR6 (0.40) | HTR6MAOACES1MAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014121036-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8263631-B2 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1982718-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION | Daiichi Sankyo Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221369-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SRD5A2, PPARD, SRD5A1 | HTR6 1464/4885MAOA 4747/4885CES1 2980/4885 |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | RNASE1, MCL1, EWSR1 | HTR6 3249/4885MAOA 4147/4885CES1 1811/4885 |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | HTR6 2952/4885MAOA 1996/4885CES1 1091/4885 |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | EGFR, ERBB2, KDR | HTR6 1193/4885MAOA 4436/4885CES1 2463/4885 |
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | HTR6 2952/4885MAOA 1996/4885CES1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.